

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUIDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated

E7	1	EPOTHILONE B HYDROXYLASE/CN
E8	1	EPOTHILONE B HYDROXYLASE (AMYCOLATOPSIS ORIENTALIS GENE EBH)/CN
E9	1	EPOTHILONE B N-OXIDE/CN
E10	1	EPOTHILONE B10/CN
E11	1	EPOTHILONE C/CN
E12	1	EPOTHILONE C BIS(TERT-BUTYLDIMETHYLSILYL) ETHER/CN
E13	1	EPOTHILONE C/D 12,13-EPOXIDASE/CN
E14	1	EPOTHILONE C/D MONOOXYGENASE/CN
E15	1	EPOTHILONE C/D SYNTHETASE/CN
E16	1	EPOTHILONE C1/CN
E17	1	EPOTHILONE C2/CN
E18	1	EPOTHILONE C3/CN
E19	1	EPOTHILONE C4/CN
E20	1	EPOTHILONE C5/CN
E21	1	EPOTHILONE C6/CN
E22	1	EPOTHILONE C7/CN
E23	1	EPOTHILONE C8/CN
E24	1	EPOTHILONE C9/CN
E25	1	EPOTHILONE D/CN

=> S E3

L1 1 "EPOTHILONE B"/CN

=> S L1 EXA SAM

SAMPLE IS IGNORED AS A SCOPE FOR THIS SEARCH

L2 1 "EPOTHILONE B"/CN

=> DIS L2 1 SAM

THE ESTIMATED COST FOR THIS REQUEST IS 1.04 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y


L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

IN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-
8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-
, (1S,3S,7S,10R,11S,12S,16R)-

MF C27 H41 N O6 S

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	13.64	13.85

STN INTERNATIONAL LOGOFF AT 09:03:08 ON 07 JUL 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	32	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	33	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:09:50 ON 07 JUL 2008

=> file pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'PCTFULL' ENTERED AT 10:10:27 ON 07 JUL 2008

COPYRIGHT (C) 2008 Univentio

FILE LAST UPDATED:

4 JUL 2008

<20080704/UP>

FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW FIELD UPTX, FIELD /EW NO LONGER AVAILBLE - SEE HELP CHANGE <<<

=> s epothilon?

L1 2484 EPOTHILON?

=> s l1/ab or l1/ti

144 EPOTHILON?/AB

129 EPOTHILON?/TI

L2 159 (EPOTHILON?/AB) OR (EPOTHILON?/TI)

=> s l2 not py>2001

817323 PY>2001

L3 53 L2 NOT PY>2001

=> s combination and l3

567168 COMBINATION

264042 COMBINATIONS

617900 COMBINATION

(COMBINATION OR COMBINATIONS)

L4 33 COMBINATION AND L3

=> d ibib 1-5

L4 ANSWER 1 OF 33 PCTFULL COPYRIGHT 2008 Univentio on STN

ACCESSION NUMBER: 2001092255 PCTFULL ED 20020826

TITLE (ENGLISH): EPOTHILONE DERIVATIVES AND METHODS FOR MAKING AND USING THE SAME

TITLE (FRENCH): DERIVES D'EPOTHILONE, PROCEDES DE PRODUCTION ET METHODES D'UTILISATION

INVENTOR(S): SANTI, Daniel;

FARDIS, Maria;

ASHLEY, Gary

PATENT ASSIGNEE(S): KOSAN BIOSCIENCES, INC.;

SANTI, Daniel;

FARDIS, Maria;

ASHLEY, Gary

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001092255	A2	20011206

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
 TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW
 MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
 CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF
 BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

PRIORITY INFO.:

US 2000-60/207,655 20000526
 US 2000-60/218,260 20000714
 US 2000-60/231,552 20000911

APPLICATION INFO.:

WO 2001-US15763 A 20010515

L4 ANSWER 2 OF 33

PCTFULL COPYRIGHT 2008 Univentio on STN

ACCESSION NUMBER:

2001083800 PCTFULL ED 20020826

TITLE (ENGLISH):

PRODUCTION OF POLYKETIDES

TITLE (FRENCH):

PRODUCTION DE POLYKETIDES

INVENTOR(S):

ARSLANIAN, Robert, L.;
 ASHLEY, Gary;
 FRYKMAN, Scott;
 JULIEN, Bryan;
 KATZ, Leonard;
 KHOSLA, Chaitan;
 LAU, Janice;
 LICARDI, Peter, J.;
 REGENTIN, Rika;
 SANTI, Daniel;
 TANG, Li

PATENT ASSIGNEE(S):

KOSAN BIOSCIENCES, INC.;
 ARSLANIAN, Robert, L.;
 ASHLEY, Gary;
 FRYKMAN, Scott;
 JULIEN, Bryan;
 KATZ, Leonard;
 KHOSLA, Chaitan;
 LAU, Janice;
 LICARDI, Peter, J.;
 REGENTIN, Rika;
 SANTI, Daniel;
 TANG, Li

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001083800	A2	20011108

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG

PRIORITY INFO.:

US 2000-09/560,367 20000428
 US 2000-60/232,696 20000914
 US 2000-60/257,517 20001221

APPLICATION INFO.: US 2001-09/825,856 20010403
US 2001-09/825,876 20010403
US 2001-60/269,020 20010413
WO 2001-US13793 A 20010426

L4 ANSWER 3 OF 33 PCTFULL COPYRIGHT 2008 Univentio on STN
ACCESSION NUMBER: 2001081341 PCTFULL ED 20020826
TITLE (ENGLISH): 9-OXA-EPOTHILON DERIVATIVES, METHOD FOR THE
PRODUCTION AND USE THEREOF IN PHARMACEUTICAL
PREPARATIONS
TITLE (FRENCH): DERIVES DE 9-OXA-EPOTHILONE, LEUR PROCEDE DE
PRODUCTION ET LEUR UTILISATION PHARMACEUTIQUE
INVENTOR(S): SCHWEDE, Wolfgang;
KLAR, Ulrich;
SKUBALLA, Werner;
BUCHMANN, Bernd;
HOFFMANN, Jens;
LICHTNER, Rosemarie
PATENT ASSIGNEE(S): SCHERING AKTIENGESELLSCHAFT;
SCHWEDE, Wolfgang;
KLAR, Ulrich;
SKUBALLA, Werner;
BUCHMANN, Bernd;
HOFFMANN, Jens;
LICHTNER, Rosemarie
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2001081341	A2	20011101

DESIGNATED STATES
W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL
SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE
DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG
CI CM GA GN GW ML MR NE SN TD TG

PRIORITY INFO.: DE 2000-100 20 899.1 20000420
APPLICATION INFO.: WO 2001-EP4551 A 20010419

L4 ANSWER 4 OF 33 PCTFULL COPYRIGHT 2008 Univentio on STN
ACCESSION NUMBER: 2001073103 PCTFULL ED 20020822
TITLE (ENGLISH): PREPARATION OF EPOTHILONE INTERMEDIATES
TITLE (FRENCH): PREPARATION D'INTERMEDIAIRES D'EPOTHILONE
INVENTOR(S): VITE, Gregory, D.;
KIM, Soong-Hoon;
HOeEFLE, Gerhard
PATENT ASSIGNEE(S): BRISTOL-MYERS SQUIBB COMPANY;
VITE, Gregory, D.;
KIM, Soong-Hoon;
HOeEFLE, Gerhard
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2001073103	A2	20011004

DESIGNATED STATES
W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG

MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
 TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
 SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
 CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
 CF CG CI CM GA GN GW ML MR NE SN TD TG
 PRIORITY INFO.: US 2000-60/191,975 20000324
 APPLICATION INFO.: WO 2001-US9620 A 20010323

 L4 ANSWER 5 OF 33 PCTFULL COPYRIGHT 2008 Univentio on STN
 ACCESSION NUMBER: 2001070716 PCTFULL ED 20020822
 TITLE (ENGLISH): A PROCESS FOR THE PREPARATION OF EPOTHILONE
 ANALOGS AND INTERMEDIATES
 TITLE (FRENCH): PREPARATION D'ANALOGUES ET D'INTERMEDIAIRES D'
 EPOTHILONE
 INVENTOR(S): LI, Wen, Sen;
 THORNTON, John, E.;
 GUO, Zhenrong;
 SWAMINATHAN, Shankar;
 MCCONLOGUE, Gary, W.
 PATENT ASSIGNEE(S): BRISTOL-MYERS SQUIBB COMPANY;
 LI, Wen, Sen;
 THORNTON, John, E.;
 GUO, Zhenrong;
 SWAMINATHAN, Shankar;
 MCCONLOGUE, Gary, W.
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001070716	A1	20010927

 DESIGNATED STATES
 W:
 AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG
 PRIORITY INFO.: US 2000-09/528,526 20000320
 APPLICATION INFO.: WO 2001-US7749 A 20010312

=> d his

(FILE 'HOME' ENTERED AT 10:09:50 ON 07 JUL 2008)

FILE 'PCTFULL' ENTERED AT 10:10:27 ON 07 JUL 2008

L1 2484 S EPOTHILON?
 L2 159 S L1/AB OR L1/TI
 L3 53 S L2 NOT PY>2001
 L4 33 S COMBINATION AND L3

=> s l4 and (taxol or paclitaxel)

9622 TAXOL
 272 TAXOLS
 9705 TAXOL
 (TAXOL OR TAXOLS)
 10390 PACLITAXEL
 72 PACLITAXELS
 10392 PACLITAXEL
 (PACLITAXEL OR PACLITAXELS)

L5 29 L4 AND (TAXOL OR PACLITAXEL)

=> s 15 and Her?
988529 HER?

L6 29 L5 AND HER?

=> s 15 and (HER2 or HER-2)
4722 HER2
118696 HER
1043 HERS
119313 HER
(HER OR HERS)
1276185 2
3260 HER-2
(HER(W)2)

L7 1 L5 AND (HER2 OR HER-2)

=> d ibib abs

L7 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2008 Univentio on STN

ACCESSION NUMBER: 1999002514 PCTFULL ED 20020515

TITLE (ENGLISH): EPOTHILONE DERIVATIVES

TITLE (FRENCH): DERIVES D'EPOTHILONE

INVENTOR(S): VITE, Gregory, D.;
BORZILLERI, Robert, M.;
KIM, Soong-Hoon;
JOHNSON, James, A.

PATENT ASSIGNEE(S): BRISTOL-MYERS SQUIBB COMPANY

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9902514	A2	19990121
------------	----	----------

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM
KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN ML MR NE SN TD TG

PRIORITY INFO.: US 1997-60/051,951 19970708

US 1997-60/067,524 19971204

APPLICATION INFO.: WO 1998-US12550 A 19980616

ABEN The present invention relates to compounds of formula (I), Q is selected from the group consisting of (II), G is selected from the group consisting of alkyl, substituted alkyl, substituted or or unsubstituted aryl, heterocyclo, (III), W is O or NR15; X is O or H,H; Y is selected from the group consisting of O; H,OR16; OR17,OR17; NOR18; H,NOR19; H,NR20R21; H,H; or CHR22; OR17OR17 can be a cyclic ketal; Z1 and Z2 are selected from the group consisting of CH2, O, NR23, S or SO2, wherein only one of Z and Z2 is a heteroatom; B1 and B2 are selected from the group consisting of OR24, or OCOR25, or 2CNR26R27; when B1 is H and Y is OH, H they can form a six-membered ring ketal or acetal; D is selected from the group consisting of NR28R29, NR30COR31 or saturated heterocycle R1, R2, R3, R4, R5, R6, R7, R13, R14, R18, R19, R20, R21, R22, R26 and R27 are

selected from the group H, alkyl, substituted alkyl, or aryl and when R1 and R2 are alkyl can be joined to form a cycloalkyl; R3 and R4 are alkyl can be joined to form a cycloalkyl; R9, R10, R16, R17, R24, R25, and R31 are selected from the group H, alkyl, or substituted alkyl; R8, R11, R12, R28, R30, R32, R33, and R30 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or heterocyclo; R15, R23 and R29 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, heterocyclo, R32C=O, R33SO2, hydroxy, O-alkyl or O-substituted alkyl, the pharmaceutically acceptable salts thereof and any hydrates, solvates or geometric, optical and stereoisomers thereof, with the proviso that compounds wherein: W and X are both O; and R1, R2, R7 are H; and R3, R4, R6, are methyl; and R8, is H or methyl; and Z1, and Z2, are CH2; and G is 1-methyl-2-(substituted-4-thiazolyl)ethenyl; and Q is as defined above are excluded.

ABFR La presente invention concerne des composes de la formule (I) dans laquelle Q est selectionne dans le groupe constitue par le groupement (II); G est selectionne dans le groupe constitue par alkyle, alkyle substitue, aryle substitue ou insubstitue, heterocyclo, le groupement (III); W est O ou NR15; X est O ou H,H; Y est selectionne dans le groupe constitue par O; H,OR16; OR17,OR17; NOR18; H,NOR19; H,NR20R21; H,H; ou CHR22; OR17,OR17 pouvant etre un cetal cyclique; Z1 et Z2 sont selectionnees dans le groupe constitue par CH2, O, NR23, S ou SO2, dans lequel seuls Z et Z2 sont un heteroatome; B1 et B2 sont selectionnees dans le groupe constitue par OR24 ou OCOR25 ou O2CNR26R27; et peuvent former ensemble un noyau cetal ou acetal a six chainons si B1 est H et Y est OH,H; D est selectionne dans le groupe constitue par NR28R29, NR30COR31 ou un heterocycle sature. R1, R2, R3, R4, R5, R6, R7, R13, R14, R18, R19, R20, R21, R22, R26 et R27 sont selectionnees dans le groupe constitue par H, alkyle, alkyle substitue ou aryle, et peuvent former ensemble un cycloalkyle si R1 et R2 ou R3 et R4 sont alkyle; R9, R10, R16, R17, R24, R25 et R31 sont selectionnees dans le groupe constitue par H, alkyle ou alkyle substitue; R8, R11, R12, R28, R30, R32, R33 et R30 sont selectionnees dans le groupe constitue par H, alkyle, alkyle substitue, aryle, aryle substitue, cycloalkyle ou heterocyclo; R15, R23 et R29 sont selectionnees dans le groupe constitue par H, alkyle, alkyle substitue, aryle, aryle substitue, cycloalkyle ou heterocyclo, R32C=O, R33SO2, hydroxy, O-alkyle ou O-alkyle substitue, leurs sels pharmaceutiquement acceptables ou leurs eventuels hydrates, solvates ou isomeres geometriques, optiques, ou stereoisomeres, a condition que soient exclus les composes dans lesquels W et X sont tous deux O; et R1, R2 et R7 sont H; et R3, R4 et R6 sont methyle; et R8 est H ou methyle; et Z1 et Z2 sont CH2; et G est

1-methyl-2-(substitue-4-thiazolyl)ethenyle; et Q est tel que defini
ci-dessus.

=> d his

(FILE 'HOME' ENTERED AT 10:09:50 ON 07 JUL 2008)

FILE 'PCTFULL' ENTERED AT 10:10:27 ON 07 JUL 2008

L1 2484 S EPOTHILON?
L2 159 S L1/AB OR L1/TI
L3 53 S L2 NOT PY>2001
L4 33 S COMBINATION AND L3
L5 29 S L4 AND (TAXOL OR PACLITAXEL)
L6 29 S L5 AND HER?
L7 1 S L5 AND (HER2 OR HER-2)

=> s l6 and (HER2 or HER-2)

4722 HER2
118696 HER
1043 HERS
119313 HER
(HER OR HERS)

1276185 2

3260 HER-2

(HER(W)2)

L8 1 L6 AND (HER2 OR HER-2)

=> s l5 and (HER2 or HER-2)

4722 HER2
118696 HER
1043 HERS
119313 HER
(HER OR HERS)

1276185 2

3260 HER-2

(HER(W)2)

L9 1 L5 AND (HER2 OR HER-2)

=> d ibib abs kwic

L9 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2008 Univentio on STN

ACCESSION NUMBER: 1999002514 PCTFULL ED 20020515

TITLE (ENGLISH): EPOTHILONE DERIVATIVES

TITLE (FRENCH): DERIVES D'EPOTHILONE

INVENTOR(S): VITE, Gregory, D.;

BORZILLERI, Robert, M.;

KIM, Soong-Hoon;

JOHNSON, James, A.

PATENT ASSIGNEE(S): BRISTOL-MYERS SQUIBB COMPANY

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9902514	A2	19990121
------------	----	----------

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM
KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE

	CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
	CF CG CI CM GA GN ML MR NE SN TD TG
PRIORITY INFO.:	US 1997-60/051,951 19970708
	US 1997-60/067,524 19971204
APPLICATION INFO.:	WO 1998-US12550 A 19980616

ABEN The present invention relates to compounds of formula (I), Q is selected from the group consisting of (II), G is selected from the group consisting of alkyl, substituted alkyl, substituted or or unsubstituted aryl, heterocyclo, (III), W is O or NR15; X is O or H,H; Y is selected from the group consisting of O; H,OR16; OR17,OR17; NOR18; H,NOR19; H,NR20R21; H,H; or CHR22; OR17OR17 can be a cyclic ketal; Z1 and Z2 are selected from the group consisting of CH2, O, NR23, S or SO2, wherein only one of Z and Z2 is a heteroatom; B1 and B2 are selected from the group consisting of OR24, or OCOR25, or 2CNR26R27; when B1 is H and Y is OH, H they can form a six-membered ring ketal or acetal; D is selected from the group consisting of NR28R29, NR30COR31 or saturated heterocycle R1, R2, R3, R4, R5, R6, R7, R13, R14, R18, R19, R20, R21, R22, R26 and R27 are selected from the group H, alkyl, substituted alkyl, or aryl and when R1 and R2 are alkyl can be joined to form a cycloalkyl; R3 and R4 are alkyl can be joined to form a cycloalkyl; R9, R10, R16, R17, R24, R25, and R31 are selected from the group H, alkyl, or substituted alkyl; R8, R11, R12, R28, R30, R32, R33, and R30 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or heterocyclo; R15, R23 and R29 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, heterocyclo, R32C=O, R33SO2, hydroxy, O-alkyl or O-substituted alkyl, the pharmaceutically acceptable salts thereof and any hydrates, solvates or geometric, optical and stereoisomers thereof, with the proviso that compounds wherein: W and X are both O; and R1, R2, R7 are H; and R3, R4, R6, are methyl; and R8, is H or methyl; and Z1, and Z2, are CH2; and G is 1-methyl-2-(substituted-4-thiazolyl)ethenyl; and Q is as defined above are excluded.

ABFR La presente invention concerne des composees de la formule (I) dans laquelle Q est selectionne dans le groupe constitue par le groupement (II); G est selectionne dans le groupe constitue par alkyle, alkyle substitue, aryle substitue ou insubstitue, heterocyclo, le groupement (III); W est O ou NR15; X est O ou H,H; Y est selectionne dans le groupe constitue par O; H,OR16; OR17,OR17; NOR18; H,NOR19; H,NR20R21; H,H; ou CHR22; OR17,OR17 pouvant etre un cetal cyclique; Z1 et Z2 sont selectionnees dans le groupe constitue par CH2, O, NR23, S ou SO2, dans lequel seuls Z et Z2 sont un heteroatome; B1 et B2 sont selectionnees dans le groupe constitue par OR24 ou OCOR25 ou 2CNR26R27; et peuvent former ensemble un noyau cetal ou acetal a six chainons si B1 est H et Y est OH,H; D est selectionne dans le groupe constitue par NR28R29, NR30COR31 ou un heterocycle sature. R1, R2, R3,

R4, R5, R6, R7, R13, R14, R18, R19, R20, R21, R22, R26 et R27 sont selectionnees dans le groupe constitue par H, alkyle, alkyle substitue ou aryle, et peuvent former ensemble un cycloalkyle si R1 et R2 ou R3 et R4 sont alkyle; R9, R10, R16, R17, R24, R25 et R31 sont selectionnees dans le groupe constitue par H, alkyle ou alkyle substitue; R8, R11, R12, R28, R30, R32, R33 et R30 sont selectionnees dans le groupe constitue par H, alkyle, alkyle substitue, aryle, aryle substitue, cycloalkyle ou heterocyclo; R15, R23 et R29 sont selectionnees dans le groupe constitue par H, alkyle, alkyle substitue, aryle, aryle substitue, cycloalkyle ou heterocyclo, R32C=O, R33SO2, hydroxy, O-alkyle ou O-alkyle substitue, leurs sels pharmaceutiquement acceptables ou leurs eventuels hydrates, solvates ou isomeres geometriques, optiques, ou stereoisomeres, a condition que soient exclus les composes dans lesquels W et X sont tous deux O; et R1, R2 et R7 sont H; et R3, R4 et R6 sont methyle; et R8 est H ou methyle; et Z1 et Z2 sont CH2; et G est 1-methyl-2-(substitue-4-thiazolyl)ethenyle; et Q est tel que defini ci-dessus.

TIEN EPOTHILONE DERIVATIVES

TIFR DERIVES D'EPOTHILONE

DETD

R
S Me
j0H
N3],]'] '
O Me
O OH O
I EpothiloneA R=H
II EpothiloneB R=Me
have been found to exert microtubule-stabilizing effects similar to TAXOL and hence cytotoxic activity against rapidly proliferating cells, such as, tumor cells or other hyperproliferative cellular disease, see .Angew. Chem. Int. Ed. Engl.,. . .

The compounds of this invention. are also useful in combination with known anti-cancer and cytotoxic agents and treatments, including radiation. If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within its approved dosage range. Compounds of formula V can be used sequentially with known anticancer or cytotoxic agents and treatment, including radiation when a combination formulation is inappropriate.

Especially useful are cytotoxic drug combinations wherein the second drug chosen acts in a different phase of the cell cycle, e.g. S phase, than the present compounds of. . .

. . .
Synthase Inhibitors,
DNA Cross Linking Agents
Topoisomerase I and II Inhibitors
DNA Alkylating Agents

Ribonucleoside Reductase Inhibitors
Cytotoxic Factors e.g. TNF-alpha or
Growth factor inhibitors e.g. HER 2 receptor MAB's
The present compounds may exist as multiple optical, geometric,
and stereoisomers. Included within the present invention are all such
isomers and. . .

. . .
potency is
accomplished following a modified procedure of Swindell, et al., (see
Swindell, C.S., Krauss, N.E., Horwitz, S.B., and Ringel, I. Biologically
active taxol analogues with deleted A-ring side chain
substituents and
variable C-2' configurations. J. Med. Chem. 34: 1176-1184, 1991). These
modifications, in part, result. . .

. . .
cells were incubated at 37' for 72 hours at which time the
tetrazolium dye, MTS at 333 gg/ml (final concentration), in
combination
with the electron coupling agent phenazine methosulfate at 25 gm (final
concentration) was added. A dehydrogenase enzyme in live cells
reduces the MTS. . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	23.30	23.51

STN INTERNATIONAL LOGOFF AT 10:14:45 ON 07 JUL 2008